ALOY suspends ATM sales after $2.21M raised

ALOY is suspending its at-the-market (ATM) continuous offering and terminating the ongoing program effective March 5, 2026.

Rhea-AI Filing Summary

ALOY is suspending its at-the-market (ATM) continuous offering and terminating the ongoing program effective March 5, 2026.

The supplement states the company sold an aggregate of 260,000 shares for gross proceeds of $2,213,472 through the sales agent under the Sales Agreement. The Sales Agreement remains in full force and effect and the company will not resume sales under the ATM unless a new prospectus supplement is filed.

Insights

Capital Markets Analyst

Suspension halts share issuance but leaves the facility available for future use.

The filing records an ATM pause effective March 5, 2026 after the company sold 260,000 shares for gross proceeds of $2,213,472. This stops incremental dilution from ATM placements until a new prospectus supplement is filed.

Timing for any restart is not provided; subsequent filings would state if and when sales resume and any changes to placement terms.

Securities Counsel

The Sales Agreement remains effective, but the continuous offering is terminated pending a new supplement.

The supplement expressly suspends and terminates the continuous offering while leaving the Sales Agreement in effect. The company notes it will not make any sales under the Sales Agreement unless a new prospectus supplement is filed.

Investors should review the ATM Prospectus Supplement's "Risk Factors" and await any new prospectus supplement for updated terms or resumption details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALOY file in the March 5, 2026 prospectus supplement?

The supplement suspends and terminates ALOY's continuous ATM offering effective March 5, 2026. It states ALOY sold 260,000 shares for gross proceeds of $2,213,472 through the Sales Agreement and that the Sales Agreement remains in effect.

How many shares has ALOY sold under its ATM program to date?

ALOY has sold an aggregate of 260,000 shares under the Sales Agreement. The supplement reports these sales generated gross proceeds of $2,213,472 through the sales agent as of the date of the supplement.

Will ALOY resume ATM sales without further filings?

No. ALOY will not make any sales under the Sales Agreement unless a new prospectus supplement is filed. The Sales Agreement itself remains in effect but sales require a subsequent prospectus supplement to resume.

Does the Sales Agreement remain active after the suspension?

Yes. The supplement states the Sales Agreement remains in full force and effect and has not been terminated, even though the continuous offering under the ATM Prospectus Supplement is suspended.

What price was ALOY's stock trading at in the supplement?

The supplement cites a last reported Nasdaq sale price of $25.88 per share on March 4, 2026. This price is provided as context in the prospectus supplement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 09:48 PM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-284626

Prospectus Supplement
(to the Prospectus dated February 10, 2025)

 

This prospectus supplement amends and supplements certain information in the prospectus supplement, dated July 1, 2025 (the “ATM Prospectus Supplement”), to the accompanying base prospectus, dated February 10, 2025 (the “Base Prospectus” and, collectively with the ATM Prospectus Supplement, the “Prospectus”) filed as part of our registration statement on Form S-3 (File No. 333-284626), relating to the offer, issuance and sale of shares of our common stock, par value $0.001 per share (“Common Stock”), from time to time, pursuant to the terms of an At-The-Market Issuance Sales Agreement (“Sales Agreement”), dated July 1, 2025, by and between us and Alexander Capital, L.P., as selling agent (the “sales agent”). Through the date hereof, we have sold an aggregate of 260,000 shares of our Common Stock for gross proceeds of $2,213,472 through the sales agent under the Sales Agreement. This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.

Our Common Stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ALOY.” On March 4, 2026, the last reported sale price for our Common Stock on Nasdaq was $25.88 per share.

The purpose of this prospectus supplement is to suspend the Sales Agreement and to terminate the continuous offering by the Company under the ATM Prospectus Supplement, effective as of the date hereof. The Company will not make any sales of Common Stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission, however, the Sales Agreement remains in full force and effect and has not been terminated.

Investing in our securities involves a high degree of risk. Please read “Risk Factors” beginning on page S-12 of the ATM Prospectus Supplement and other documents and information contained or incorporated by reference in this prospectus supplement and the ATM Prospectus Supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.

The date of this prospectus supplement is March 5, 2026.